Radimmune Therapeutics has selected Goodwin Biotechnology to develop a process and manufacture it’s lead therapeutic oncology candidate for clinical development, a therapeutic grade IgG monoclonal antibody (mAb) conjugate. The conjugate will be radiolabeled with 213Bi and administered to patients in a Phase I clinical study for the treatment of melanoma.   “Melanoma is by far the deadliest form of skin cancer,” said Robert Wittig, chief operating officer, Radimmune Therapeuti...